Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma

P76.18 Tissue- and Plasma-Based Landscape of Resistance to Osimertinib

(2021) S.M. Lim et al.   Journal of Thoracic Oncology

Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients

(2020) Feng Li et al.   Cancers

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

(2019) Jhanelle E. Gray et al.   CLINICAL CANCER RESEARCH

Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib

(2019) Jun Zhao et al.   LUNG CANCER

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Precision oncology in non-small-cell lung cancer: opportunities and challenges

(2018) Chul Kim et al.   Nature Reviews Clinical Oncology

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA

(2018) Davina Gale et al.   PLoS One

Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling

(2018) Vincent Plagnol et al.   PLoS One

Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer

(2018) Teresa Morán et al.   Oncotarget

Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.

(2018) Frances A. Shepherd et al.   JOURNAL OF CLINICAL ONCOLOGY

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

(2018) Rajeswara Rao Arasada et al.   Nature Communications

Electric Field–Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer Assessment

(2018) Fang Wei et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective

(2017) Mathilde Postel et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

(2017) Collin M Blakely et al.   NATURE GENETICS

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients

(2017) Liwen Xiong et al.   Oncotarget

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib

(2016) Mizuki Nishino et al.   ACADEMIC RADIOLOGY

Complication rates of CT-guided transthoracic lung biopsy: meta-analysis

(2016) W. J. Heerink et al.   EUROPEAN RADIOLOGY

Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance

(2016) Jinfeng He et al.   PATHOLOGY & ONCOLOGY RESEARCH

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients

(2016) Anja Lisa Riediger et al.   Scientific Reports

Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer

(2016) Adrian G. Sacher et al.   JAMA Oncology

Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients

(2016) Kikuya Kato et al.   Scientific Reports

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

(2015) T. Mok et al.   CLINICAL CANCER RESEARCH

Noninvasive Saliva-basedEGFRGene Mutation Detection in Patients with Lung Cancer

(2014) Fang Wei et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

(2014) G. R. Oxnard et al.   CLINICAL CANCER RESEARCH

Liquid Biopsies: Genotyping Circulating Tumor DNA

(2014) Luis A. Diaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI

(2013) Mizuki Nishino et al.   Journal of Thoracic Oncology

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

(2013) Muhammed Murtaza et al.   NATURE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

(2012) T. Forshew et al.   Science Translational Medicine